Elevation Point Wealth Partners LLC Acquires Shares of 44,201 Teva Pharmaceutical Industries Ltd. $TEVA

Elevation Point Wealth Partners LLC acquired a new position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the first quarter, Holdings Channel reports. The institutional investor acquired 44,201 shares of the company’s stock, valued at approximately $1,331,000.

Other large investors have also recently made changes to their positions in the company. Aster Capital Management DIFC Ltd purchased a new position in Teva Pharmaceutical Industries in the fourth quarter worth about $25,000. Allworth Financial LP increased its stake in Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after acquiring an additional 329 shares during the last quarter. Grove Bank & Trust raised its position in Teva Pharmaceutical Industries by 300.0% during the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after purchasing an additional 750 shares during the period. EverSource Wealth Advisors LLC raised its position in Teva Pharmaceutical Industries by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after purchasing an additional 345 shares during the period. Finally, Global Retirement Partners LLC lifted its stake in shares of Teva Pharmaceutical Industries by 27.3% in the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after purchasing an additional 292 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Bank of America lifted their target price on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 9th. Barclays increased their price target on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. JPMorgan Chase & Co. raised their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. UBS Group lifted their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Finally, Truist Financial boosted their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $41.78.

Teva Pharmaceutical Industries Trading Down 0.2%

TEVA opened at $34.55 on Monday. The stock has a market cap of $39.73 billion, a price-to-earnings ratio of 25.98, a P/E/G ratio of 4.23 and a beta of 0.86. The stock’s 50 day moving average price is $33.96 and its 200-day moving average price is $32.57. Teva Pharmaceutical Industries Ltd. has a one year low of $14.99 and a one year high of $37.35. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The firm had revenue of $3.98 billion for the quarter. On average, equities analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.97 EPS for the current year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 21,258 shares of the stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $35.31, for a total value of $750,619.98. Following the sale, the executive vice president owned 63,647 shares in the company, valued at $2,247,375.57. This trade represents a 25.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Richard Daniell sold 30,000 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total value of $1,062,000.00. Following the sale, the executive vice president owned 55,755 shares of the company’s stock, valued at approximately $1,973,727. This trade represents a 34.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 465,931 shares of company stock worth $16,332,989 over the last ninety days. Corporate insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.